Erschienen in:
12.09.2023 | Letter to the Editor
Glioblastoma immunotherapy: time for hope?
verfasst von:
Giacomo Sferruzza, Gaetano Finocchiaro
Erschienen in:
Neurological Sciences
|
Ausgabe 1/2024
Einloggen, um Zugang zu erhalten
Excerpt
The DCVax-L study has recently shown a significant survival gain in glioblastoma (GBM) patients treated with dendritic cell (DC) immunotherapy versus an externally controlled cohort [
1]. The initial case–control design of the study required modification partly because patients in the original control arm underwent apheresis and requested their cells to be used for immunotherapy at recurrence. …